. 2021 May 5;193(21):E771–E776. doi: 10.1503/cmaj.210531
© 2021 CMA Joule Inc. or its licensors
This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY-NC-ND 4.0) licence, which permits use, distribution and reproduction in any medium, provided that the original publication is properly cited, the use is noncommercial (i.e., research or educational use), and no modifications or adaptations are made. See: https://creativecommons.org/licenses/by-nc-nd/4.0/
Figure 2:
A proposed 3-stage framework for managing tocilizumab shortage in Canada.